An investigation on behalf of investors of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) in connection with the proposed takeover was announced and NASDAQ:KYTH stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/29/2015 -- An investigation on behalf of investors, who currently hold shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH), was announced concerning whether the takeover of Kythera Biopharmaceuticals Inc by Allergan plc for a value of $75 per share is unfair to NASDAQ:KYTH stockholders.
Investors who purchased shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) and currently hold any of those NASDAQ:KYTH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Kythera Biopharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:KYTH investors in connection with the proposed acquisition.
On June 17, 2015, Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced that they have entered into an agreement under which Allergan has agreed to acquire Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion, subject to the fulfillment of certain customary conditions summarized below.
However, given that at least one analyst has set the high target price for NASDAQ: KYTH shares at $85.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:KYTH stockholders. More specifically, the investigation concerns whether the Kythera Biopharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) closed on June 25, 2015, at $75.15 per share.
Those who are current investors in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com